Log in to search using one of your social media accounts:

 

Researchers identify possible new target in fight against lung cancer
(Boston University School of Medicine) Researchers at Boston University School of Medicine have identified a molecule called miR-124 in non-small cell lung cancer cells that plays a regulatory role in the cancer cells' fate -- determining whether or not the specific subtype of cancer cell will undergo programmed cell death. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news

Regulation of autophagy, NF-{kappa}B signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells
KRAS mutant non–small cell lung cancer (NSCLC) may be classified into epithelial or mesenchymal subtypes. Despite having the same "driver" mutation, mesenchymal NSCLCs are less responsive than are epithelial NSCLCs to inhibition of the RAS pathway. Identifying alternative networks that promote survival specifically in mesenchymal NSCLC may lead to more effective treatments for this subtype. Through their numerous targets in cellular signaling pathways, noncoding microRNAs (miRNAs) often function as tumor suppressors or oncogenes. In particular, some miRNAs regulate the epithelial-mesenchymal transition (EMT...
Source: Signal Transduction Knowledge Environment - September 12, 2017 Category: Science Authors: Mehta, A. K., Hua, K., Whipple, W., Nguyen, M.-T., Liu, C.-T., Haybaeck, J., Weidhaas, J., Settleman, J., Singh, A. Tags: STKE Research Articles Source Type: news

Anti-PD 1 Drug Extends PFS in Stage III NSCLC (CME/CE)
(MedPage Today) -- Progression-free survival three times longer with durvalumab after chemoradiation (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - September 11, 2017 Category: Consumer Health News Source Type: news

Longer Progression - Free Survival for Durvalumab in NSCLC
Longer median progression - free survival from randomization, higher response rate with durvalumab (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 11, 2017 Category: Respiratory Medicine Tags: Internal Medicine, Oncology, Pathology, Pharmacy, Pulmonology, Radiology, Surgery, Conference News, Source Type: news

EGFR-Mutant NSCLC Gains New First-Line Treatment
(MedPage Today) -- PFS doubled with osimertinib versus standard therapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 10, 2017 Category: Hematology Source Type: news

ARMO BioSciences's Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival
It is particularly promising to see these high, durable responses in advanced NSCLC patients with low as well as high PD-L1 expression and in intermediate to poor risk advanced RCC patients who have received 2 or more prior therapies."09/11/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 10, 2017 Category: Urology & Nephrology Source Type: news

Durvalumab Boots PFS Even in Stage 3 Lung Cancer Durvalumab Boots PFS Even in Stage 3 Lung Cancer
Immunotherapy is continuing its march: the first trial of an anti-PD-L1 inhibitor in stage 3 non-small cell lung cancer has shown an impressive increase in progression-free survival.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 9, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Osimertinib Poised To Be New First-line Standard EGFRm NSCLC Osimertinib Poised To Be New First-line Standard EGFRm NSCLC
Osimertinib, a third-generation EGFR inhibitor, significantly improved PFS over current standard-of-care therapies in advanced NSCLC harboring EGFR mutations.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 9, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer
(European Society for Medical Oncology) Osimertinib improves progression-free survival by 54% compared to standard first line therapy in patients with EGFR mutated non-small-cell lung cancer (NSCLC), according to late-breaking results from the FLAURA trial presented today at the ESMO 2017 Congress in Madrid. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 9, 2017 Category: Cancer & Oncology Source Type: news

Alectinib Activity in CNS Metastases in Patients With ALK+ NSCLC Alectinib Activity in CNS Metastases in Patients With ALK+ NSCLC
Two studies report impressive activity for the ALK inhibitor, alectinib, in patients with advanced ALK+ NSCLC -- both in treatment-naive patients and those who have progressed on prior therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
Roche today announced results from the global phase III ALUR study showing that Alecensa ® significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by 85% compared to chemotherapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), who had progressed following treatment with platinum-based chemothe rapy and crizotinib (hazard ratio [HR]=0.15, 95% CI: 0.08-0.29, p (Source: Roche Media News)
Source: Roche Media News - September 6, 2017 Category: Pharmaceuticals Source Type: news

Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
Roche today announced results from the global phase III ALUR study showing that Alecensa ® significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by 85% compared to chemotherapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), who had progressed following treatment with platinum-based chemothe rapy and crizotinib (hazard ratio [HR]=0.15, 95% CI: 0.08-0.29, p (Source: Roche Investor Update)
Source: Roche Investor Update - September 6, 2017 Category: Pharmaceuticals Source Type: news

Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC
(European Society for Medical Oncology) Data from two separate phase 3 studies to be presented at the ESMO 2017 Congress in Madrid, show alectinib's particular central nervous system (CNS) activity in patients with advanced non-small cell lung cancer involving a mutation of the anaplastic lymphoma kinase gene (ALK-positive NSCLC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 5, 2017 Category: Cancer & Oncology Source Type: news

No Need for CT Scans in NSCLC Postsurgery Follow-up? No Need for CT Scans in NSCLC Postsurgery Follow-up?
Intensive follow-up with CT scanning after successful surgery for early-stage non-small cell lung cancer may not improve survival, say French scientists.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

IFCT-0302 results question role of CT-scan in NSCLC post-surgery follow-up
(European Society for Medical Oncology) The optimal follow-up protocol for patients with completely resected non-small cell lung cancer (NSCLC) remains elusive after results of the IFCT-0302 trial, to be presented at the ESMO 2017 Congress in Madrid, did not show a difference in overall survival (OS) between patients who received computed tomography (CT) scans as part of their follow-up, and those who did not. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 30, 2017 Category: Cancer & Oncology Source Type: news

Does Thoracoscopic Lobectomy Improve Long-term Outcomes in Early Lung Cancer? Does Thoracoscopic Lobectomy Improve Long-term Outcomes in Early Lung Cancer?
Video-assisted thoracoscopic (VATS) lobectomy is associated with shorter hospital stay and non-inferior long-term survival in patients with stage 1 non-small-cell lung cancer (NSCLC), compared with open lobectomy, according to findings from the National Cancer Data Base.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 24, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Nearly One-Third of Mesothelioma Patients Remain Untreated
A new report from the National Cancer Institute (NCI) shows between 20 and 30 percent of malignant mesothelioma patients do not receive any cancer treatment. The study, “Patterns of care and survival among patients with malignant mesothelioma in the United States,” published August 10 in the journal Lung Cancer, aimed to describe the patterns of care and subsequent survival among mesothelioma patients in the U.S. while adjusting for patient demographics and pre-existing health conditions. Using the NCI’s Surveillance, Epidemiology, and End Results (SEER) data, researchers discovered significant differenc...
Source: Asbestos and Mesothelioma News - August 21, 2017 Category: Environmental Health Authors: Matt Mauney Tags: amount of mesothelioma patients eligible for surgery checkpoint inhibitors clinical trial enrollment cytoreduction surgery heated chemotherapy pleural mesothelioma heated intraperitoneal chemotherapy immunotherapy mesothelioma keytruda Lin Source Type: news

Tumor-educated Platelets Noninvasively Detect Non-small-cell Lung Cancer Tumor-educated Platelets Noninvasively Detect Non-small-cell Lung Cancer
A new signature detection platform uses tumor-educated platelet (TEP) RNA profiles to detect non-small-cell lung cancer (NSCLC).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 16, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Combining Immunotherapy Agents in NSCLC: Is MYSTIC a Misstep? Combining Immunotherapy Agents in NSCLC: Is MYSTIC a Misstep?
Though they have received a lot of hype as the heir apparent in lung cancer therapy, the early signals on combining immunotherapies are not reassuring, cautions Dr Jack West.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 16, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Panel Backs PD-L1 Drugs for First Line in NSCLC
(MedPage Today) -- Roles for three approved drugs in ASCO guideline (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 15, 2017 Category: Hematology Source Type: news

Examination of CTC Profiles in NSCLC Molecular Subgroups Examination of CTC Profiles in NSCLC Molecular Subgroups
What number of circulating tumor cells is associated with a poor prognosis in advanced NSCLC?Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Guidelines Updated on Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer (FREE)
By the Editors The American Society of Clinical Oncology has updated its 2015 guidelines on systemic therapy for patients with … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 15, 2017 Category: Primary Care Source Type: news

Blood biopsy test reads platelets to detect human lung cancer
(Cell Press) Researchers in the Netherlands have designed a different approach to the liquid biopsy. Rather than looking for evidence of cancer DNA or other biomarkers in the blood, their test (called thromboSeq) could diagnose non-small cell lung cancer with close to 90 percent accuracy by detecting tumor RNA absorbed by circulating platelets, also known as thrombocytes. Non-small cell lung cancers make up the majority of lung cancer cases. The research appears Aug. 14 in Cancer Cell. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 14, 2017 Category: Cancer & Oncology Source Type: news

WIN Consortium to conduct targeted tri-therapy trial for NSCLC
French non-profit healthcare network WIN Consortium (WIN) is set to conduct a clinical trial (SPRING) of a new three targeted therapies combination as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC), following appro … (Source: Drug Development Technology)
Source: Drug Development Technology - August 9, 2017 Category: Pharmaceuticals Source Type: news

Better Results in NSCLC with Higher Dose of ALK Inhibitor (CME/CE)
(MedPage Today) -- Response, PFS improved with 180 mg of brigatinib (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 7, 2017 Category: Primary Care Source Type: news

July ’s top stories: NCI and COG’s paediatric precision cancer trial, AstraZeneca’s NSCLC trial results
NIH ’s unit NCI and the COG initiated patient enrolment in a paediatric Phase II clinical trial to evaluate targeted cancer medicines, and AstraZeneca reported positive results from the FLAURA trial of Tagrisso to treat patients with locally advanced … (Source: Drug Development Technology)
Source: Drug Development Technology - August 6, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Roche ’s Alecensa Priority Review for initial treatment of people with ALK-positive lung cancer
Roche announced today that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental New Drug Application (sNDA) and granted Priority Review for Alecensa® (alectinib) as an initial (first-line) treatment for people with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Source: Roche Investor Update)
Source: Roche Investor Update - August 3, 2017 Category: Pharmaceuticals Source Type: news

Afatinib cost effective for EGFRm+ NSCLC in France
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2017 Category: Drugs & Pharmacology Source Type: news

AstraZeneca ’s Tagrisso improves progression-free survival in Phase III NSCLC trial
AstraZeneca has reported positive results from the Phase III FLAURA trial of Tagrisso (osimertinib) to treat patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC). (Source: Drug Development Technology)
Source: Drug Development Technology - July 30, 2017 Category: Pharmaceuticals Source Type: news

Eribulin Fails to Improve Over Physician ’s Choice in NSCLC
A phase III trial failed to demonstrate superiority of eribulin over treatment of physician ’s choice in patients with heavily pretreated non–small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 28, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Bayer ’ s Drug Failed to Improve Mesothelioma Survival
Drug manufacturers announced disappointing ends recently to two different clinical trials involving pleural mesothelioma, dampening earlier enthusiasm over the promise of immunotherapy. Anetumab ravtansine, manufactured by Bayer, and tremelimumab, from drugmaker AstraZeneca, failed an effectiveness test as a stand-alone, second-line treatment for mesothelioma, according to both manufacturers. “Malignant pleural mesothelioma is a very difficult-to-treat tumor, and we had hoped for a better outcome for patients,” said Robert LaCaze, an executive vice president at Bayer. Although trial officials have not released ...
Source: Asbestos and Mesothelioma News - July 27, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: anetumab ravtansine astrazeneca cancer drug bayer cancer drug bayer mesothelioma drug mesothelioma clinical trials tremelimumab Source Type: news

Atezolizumab Response Tied to Selected PD-LI Expression in NSCLC (CME/CE)
(MedPage Today) -- PD-L1 status may be predictive biomarker (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - July 23, 2017 Category: Consumer Health News Source Type: news

Proton Tx Plus Chemo Seen Beneficial in NSCLC (CME/CE)
(MedPage Today) -- Median overall survival of 26.5 months in inoperable stage III disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 21, 2017 Category: Hematology Source Type: news

CHMP recommends EU approval for Roche ’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for TECENTRIQ ® (atezolizumab) as a monotherapy for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy. (Source: Roche Media News)
Source: Roche Media News - July 21, 2017 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval for Roche ’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for TECENTRIQ ® (atezolizumab) as a monotherapy for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - July 21, 2017 Category: Pharmaceuticals Source Type: news

Mesothelioma Clinical Trial Combines Immunotherapy Drugs
Dr. Tawee Tanvetyanon at the Moffitt Cancer Center in Tampa rarely sounds this enthused about the future prospects for patients with pleural mesothelioma. Finally, he has something promising to offer. Tanvetyanon is the principal investigator of a much-anticipated phase II clinical trial involving an immunotherapy drug combination with considerable potential for extending survival. “This is exciting. We now can offer something with realistic hope,” he told Asbestos.com. “We haven’t had anything like this for mesothelioma in a long time. I really look forward to speaking with these patients now.&rdqu...
Source: Asbestos and Mesothelioma News - July 13, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Abramson Cancer Center Aduro Biotech CRS-207 Dr. Tawee Tanvetyanon FDA approval Keytruda improving mesothelioma prognosis Merck mesothelioma chemotherapy mesothelioma clinical trials mesothelioma immunotherapy moffitt cancer center m Source Type: news

Phase II Ssudy: Radiotherapy dose increase to hypoxic NSCLC lesions
(Society of Nuclear Medicine) Fluorine-18-fluoromisonidazole (FMISO) is a PET radiotracer that is widely used to diagnose hypoxia (insufficient oxygen supply to tissue), and non-small cell lung cancer (NSCLC) patients with FMISO uptake are known to face a poor prognosis. A multicenter French Phase II study featured in the July issue of The Journal of Nuclear Medicine investigated whether a selective radiotherapy dose increase to tumor areas with significant FMISO uptake in NSCLC patients could improve outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 10, 2017 Category: Cancer & Oncology Source Type: news

Phase II Study: Radiotherapy dose increase to hypoxic NSCLC lesions
(Society of Nuclear Medicine) Fluorine-18-fluoromisonidazole (FMISO) is a PET radiotracer that is widely used to diagnose hypoxia (insufficient oxygen supply to tissue), and non-small cell lung cancer (NSCLC) patients with FMISO uptake are known to face a poor prognosis. A multicenter French Phase II study featured in the July issue of The Journal of Nuclear Medicine investigated whether a selective radiotherapy dose increase to tumor areas with significant FMISO uptake in NSCLC patients could improve outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 10, 2017 Category: Cancer & Oncology Source Type: news

Adjuvant TKI Therapy for Early-Stage EGFR Mutation-Positive NSCLC Adjuvant TKI Therapy for Early-Stage EGFR Mutation-Positive NSCLC
Is disease-free survival an appropriate endpoint in studies where the goal is cure?Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 7, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

European Commission approves Novartis's Zykadia for ALK-positive NSCLC patients
The European Commission (EC) has given approval for the expansion of use for Swiss healthcare company Novartis's Zykadia (ceritinib) drug for treatment of advanced non-small cell lung cancer (NSCLC) in the EU.   (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 2, 2017 Category: Pharmaceuticals Source Type: news

Pembrolizumab cost effective for metastatic  NSCLC in USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2017 Category: Drugs & Pharmacology Source Type: news

New ASCO Guideline for NSCLC:'Precision Medicine at Its Best'New ASCO Guideline for NSCLC:'Precision Medicine at Its Best '
According to Dr Kris, new ASCO guidelines for adjuvant management of NSCLC stress the importance of multimodality care.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Genentech and Epizyme to study tazemetostat in Phase Ib/II combination trial for NSCLC
Roche Group ’s biotechnology subsidiary Genentech has expanded clinical collaboration with biopharmaceutical firm Epizyme to investigate the combination of atezolizumab (Tecentriq) and tazemetostat in a Phase Ib/II clinical trial to treat non-small-ce… (Source: Drug Development Technology)
Source: Drug Development Technology - June 26, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Targeted Drug Combo for Lung Cancer FDA Approves Targeted Drug Combo for Lung Cancer
For the first time, the FDA has approved treatment for metastatic non-small cell lung cancer with BRAF V600E mutation.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 23, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves diagnostic that simultaneously screens for multiple lung cancer types
The FDA said today that it awarded premarket approval to Thermo Fisher Scientific’s (NYSE:TMO) next-gen sequencing-based test that can simultaneously screen tumor samples for biomarkers associated with 3 approved therapies for non-small cell lung cancer. The company’s Oncomine Dx Target Test evaluates 23 genes associated with non-small cell lung cancer. The tests results could help physicians match patients to therapies in days. Traditionally, that process can take several weeks since clinicians are forced to screen samples for individual biomarkers. Get the full story at our sister site, Drug Delivery Business...
Source: Mass Device - June 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diagnostics Food & Drug Administration (FDA) Oncology Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat Novartis Pfizer Thermo Fisher Scientific Source Type: news

Immunotherapy: New Era for NSCLC Management Immunotherapy: New Era for NSCLC Management
Immunotherapy for advanced NSCLC has altered clinical care, shaken up how guidelines are developed, and changed how trials are conducted.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2017 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Nivolumab Doesn ’ t Up PFS in Stage IV or Recurrent NSCLC
Findings in patients with previously untreated disease with PD - L1 expression level of ≥ 5 percent (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 22, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Pulmonology, Journal, Source Type: news

PD-1 Inhibitor Disappoints as First-Line Tx in NSCLC (CME/CE)
(MedPage Today) -- But agent had favorable safety profile versus chemo (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 21, 2017 Category: Primary Care Source Type: news

Should early-stage breast cancer patients receive CT?
Not performing chest CT on patients with stage I or II breast cancer would...Read more on AuntMinnie.comRelated Reading: NCCN recommends Sirtex's microspheres New NCCN guidelines include breast tomo NCCN guidelines to intermingle with decision support NCCN publishes cancer imaging guidelines NCCN updates non-small cell lung cancer guidelines (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 21, 2017 Category: Radiology Source Type: news